TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20660053

Group type: EXPERIMENTAL
Intervention: Primary Aldosteronism (PA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Unilateral adrenalectomy for aldosterone-producing adenoma (APA)
Number of subjects: 52
Study: 20660788

Group type: EXPERIMENTAL
Intervention: Patients developing IRIS episodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-1(+) CD4(+) T cells in IRIS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulatory T cells of IRIS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRIS patients
Number of subjects: 0
Study: 20660808

Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT imaging
Number of subjects: 107

Group type: COMPARATOR
Intervention: CT angiography alone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Perfusion imaging alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combined PET and CT protocols
Number of subjects: 107
Study: 20661232

Group type: EXPERIMENTAL
Intervention: EPOCH-F regimen (infusional etoposide, VCR, adriamycin, prednisone, CY, fludarabine)
Number of subjects: 22
Study: 20661680

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Processed EEG monitoring
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fore-Sight monitor for cerebral oximetry
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lactate flux
Number of subjects: 26
Study: 20662793

Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with carboplatin (i.v. gemcitabine at 1000 mg/m² on days 1 and 8, and i.v. carboplatin at AUC 5 on day 1 of a 21-day cycle)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with carboplatin
Number of subjects: 48
Study: 20662848

Group type: EXPERIMENTAL
Intervention: Removal of the internal limiting membrane (ILM) during epiretinal membrane surgery
Number of subjects: 22
Study: 20663751

Group type: EXPERIMENTAL
Intervention: Interactive website for weight loss maintenance (consistent users n = 212)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Interactive website for weight loss maintenance (minimal users n = 75)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Number of log-ins
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Minutes on the website
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Number of weight entries
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Number of exercise entries
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Sessions with additional use of website features after weight entry
Number of subjects: 348
Study: 20663944

Group type: EXPERIMENTAL
Intervention: Oral busulfan 12 mg/kg plus melphalan 140 mg/m2
Number of subjects: 767

Group type: COMPARATOR
Intervention: Melphalan 200 mg/m2
Number of subjects: 767
Study: 20664026

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2285

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 2285
Study: 20664181

Group type: EXPERIMENTAL
Intervention: Group therapy for MCI patients combining psychoeducation, cognitive rehabilitation, and cognitive-behavioral therapy.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waiting-list control group (30 patients).
Number of subjects: 93
Study: 20666569

Group type: EXPERIMENTAL
Intervention: Low-dose ASA (75-325 mg daily)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Upper GI symptoms
Number of subjects: 340
Study: 20667078

Group type: EXPERIMENTAL
Intervention: Hormone therapy (specifics not provided)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2400
Study: 20668228

Group type: EXPERIMENTAL
Intervention: Autologous T cells genetically engineered to express anti-CD19 CAR
Number of subjects: 1

Group type: COMPARATOR
Intervention: Preparative chemotherapy regimen
Number of subjects: 1
Study: 20668251

Group type: EXPERIMENTAL
Intervention: Food selection meeting SMI standards
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Food selection meeting IOM recommendations
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Saturated fat selection
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Mean energy selection
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Mean plate waste
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Mean energy intake
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Plate waste differences
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Nutrient recommendations met
Number of subjects: 2049
Study: 20669280

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 594

Group type: COMPARATOR
Intervention: Methotrexate only
Number of subjects: 594
Study: 20671118

Group type: EXPERIMENTAL
Intervention: LMP2-specific effector CD8(+) T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel LMP2 mRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMP2 as an immunotherapeutic target
Number of subjects: 0
Study: 20671408

Group type: EXPERIMENTAL
Intervention: Metformin (1250 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (normo-androgenic women)
Number of subjects: 10
Study: 20671544

Group type: EXPERIMENTAL
Intervention: Tenofovir use
Number of subjects: 538
Study: 20672318

Group type: EXPERIMENTAL
Intervention: Personalized exercise program
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sedentary activity
Number of subjects: 16
Study: 20673344

Group type: EXPERIMENTAL
Intervention: AUDS patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: MDE patients
Number of subjects: 32
Study: 20673547

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 33
Study: 20674059

Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia (Group 2b)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Normoglycemics (Group 1)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Newly diagnosed hyperglycemia (Group 2)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Unrecognized glycemic disorder (Group 2a)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Recognized diabetes (Group 3)
Number of subjects: 255
Study: 20675064

Group type: EXPERIMENTAL
Intervention: Pulsed-dose-rate (PDR) brachytherapy, 49.8 Gy in 83 consecutive fractions of 0.6 Gy each hour, total treatment time 3 to 4 days.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy, 32 Gy in eight fractions of 4 Gy, twice daily.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Age <50 years (49 patients)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Age ≥50 years (225 patients)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Antihormonal treatment (AHT) applied (91% of patients)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: No antihormonal treatment (AHT not applied, 9% of patients)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Lobular histology (45 patients)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Other histologies (229 patients)
Number of subjects: 274
Study: 20675208

Group type: EXPERIMENTAL
Intervention: Mail-distributed approach
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OP-direct approach
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OP-subsequent approach
Number of subjects: 45
Study: 20675660

Group type: EXPERIMENTAL
Intervention: Late microvascular obstruction (MO) assessed by MRI
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Early microvascular obstruction (MO) assessed by MRI
Number of subjects: 438

Group type: COMPARATOR
Intervention: Traditional prognostic markers
Number of subjects: 438
Study: 20677256

Group type: EXPERIMENTAL
Intervention: Single breathhold T2* MR technique
Number of subjects: 49
Study: 20677285

Group type: EXPERIMENTAL
Intervention: Early allograft dysfunction (EAD) defined by bilirubin >or=10mg/dL on day 7, INR >or=1.6 on day 7, and ALT/AST >2000 IU/L within the first 7 days.
Number of subjects: 300

Group type: COMPARATOR
Intervention: No EAD (control group)
Number of subjects: 300
Study: 20679083

Group type: EXPERIMENTAL
Intervention: Descemetorhexis in endothelial keratoplasty
Number of subjects: 0
Study: 20681993

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) in obese men
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Free Testosterone (FT) in obese men
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carotid Intima-Media Thickness (cIMT) related to GH
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carotid Intima-Media Thickness (cIMT) related to FT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT) correlation with GH and FT
Number of subjects: 50
Study: 20683637

Group type: EXPERIMENTAL
Intervention: 17-AAG (17-allylamino-17-demethoxygeldanamycin), administered weekly, intravenous
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 17-AAG (17-allylamino-17-demethoxygeldanamycin)
Number of subjects: 14
Study: 20685256

Group type: EXPERIMENTAL
Intervention: Fludarabine (30 mg/m² once daily i.v. on days -5, -4, -3, and -2), Cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7, and -6), Thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2, and -1)
Number of subjects: 28
Study: 20685491

Group type: EXPERIMENTAL
Intervention: Calcium 1200 to 2000 mg/d
Number of subjects: 6

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 6

Group type: COMPARATOR
Intervention: Calcium with or without vitamin D
Number of subjects: 6
Study: 20687947

Group type: EXPERIMENTAL
Intervention: IL-2 for 80 weeks (previously received IL-2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IL-2 for 80 weeks (newly initiating IL-2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IL-2 for 80 weeks (both groups)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IL-2 administration
Number of subjects: 80
Study: 20688032

Group type: EXPERIMENTAL
Intervention: Myocardial fibrosis group (136 patients)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Extent of fibrosis
Number of subjects: 217

Group type: COMPARATOR
Intervention: Patients without fibrosis (81 patients)
Number of subjects: 217
Study: 20688481

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 0
Study: 20688734

Group type: EXPERIMENTAL
Intervention: Fundus autofluorescence (FAF) imaging
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Correlation of atrophic lesion width with SD-OCT parameters
Number of subjects: 21
Study: 20688739

Group type: EXPERIMENTAL
Intervention: High-resolution, genome-wide, single nucleotide polymorphism (SNP) mapping arrays
Number of subjects: 58
Study: 20688740

Group type: EXPERIMENTAL
Intervention: Children born prematurely with ROP
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control subjects (age-matched children from a national survey)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Children with a history of ROP
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Children with hyperopia
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Children with myopia
Number of subjects: 108
Study: 20688894

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (P(I)max)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressure (P(E)max)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient for P(I)max
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient for P(E)max
Number of subjects: 20
Study: 20688921

Group type: EXPERIMENTAL
Intervention: Chest tube drainage
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 168
Study: 20688924

Group type: EXPERIMENTAL
Intervention: Baseline Dyspnea Index
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: University of California San Diego Shortness of Breath Questionnaire
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Depression score
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 4-m walk time
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FVC (Forced Vital Capacity)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diffusing capacity of the lung for carbon monoxide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BMI (Body Mass Index)
Number of subjects: 52
Study: 20689221

Group type: EXPERIMENTAL
Intervention: Resolute stent
Number of subjects: 112
Study: 20689350

Group type: EXPERIMENTAL
Intervention: Receptive music therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20693562

Group type: EXPERIMENTAL
Intervention: Pressure-cornea-vascular index (PCVI)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: PCVI
Number of subjects: 415
Study: 20696979

Group type: EXPERIMENTAL
Intervention: IOP reduction (from 18.0 to 14.8 mm Hg)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Patients with abnormal anticardiolipin antibody levels
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 216

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 216
Study: 20697802

Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m²
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sagopilone 22 mg/m²
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sagopilone (both doses)
Number of subjects: 65
Study: 20698927

Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12 treatment (0.8 mg folic acid, 0.4 mg vitamin B12, 40 mg vitamin B6)
Number of subjects: 6837

Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 6837

Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12 treatment
Number of subjects: 6837
Study: 20700595

Group type: EXPERIMENTAL
Intervention: Covered stents (n = 43, group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Coil embolization (n = 46, group B)
Number of subjects: 89
Study: 20701823

Group type: EXPERIMENTAL
Intervention: Quetiapine (dose-dependent)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quetiapine (high doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quetiapine (low doses)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls (N=28)
Number of subjects: 22
Study: 20702138

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m², oxaliplatin 85 mg/m², folinate 200 mg/m², fluorouracil 3200 mg/m² for 48 h continuous infusion)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (induction treatment for a maximum of 6 months, followed by maintenance treatment with bevacizumab 5 mg/kg every 2 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 57
Study: 20703446

Group type: EXPERIMENTAL
Intervention: Fed state (n=8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting state (n=4)
Number of subjects: 12
Study: 20704493

Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 82
Study: 20705688

Group type: EXPERIMENTAL
Intervention: Intermountain Risk Score (IMRS)
Number of subjects: 3927
Study: 20705799

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (540 μg budesonide bid) for 14 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Younger group (aged 18 to 39 years)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Middle-aged group (aged 40 to 59 years)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Older group (aged 60 to 86 years)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Combined younger and middle-aged groups
Number of subjects: 106

Group type: COMPARATOR
Intervention: Older group vs younger group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Corrected J'awno in younger group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Corrected Cano in younger group
Number of subjects: 106
Study: 20707601

Group type: EXPERIMENTAL
Intervention: Mipomersen (200 or 160 mg) administered subcutaneously for 26 weeks
Number of subjects: 34
Study: 20707781

Group type: EXPERIMENTAL
Intervention: Naltrexone implants
Number of subjects: 60
Study: 20708849

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a total dose of 60 Gy in three fractions for peripheral lesions and four fractions for central lesions.
Number of subjects: 40
Study: 20709820

Group type: COMPARATOR
Intervention: Single-nucleotide polymorphism in BICD1
Number of subjects: 2380
Study: 20709904

Group type: EXPERIMENTAL
Intervention: Long-term follow-up data on GPS patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High serum vitamin B(12) levels
Number of subjects: 25
Study: 20710052

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily with tenofovir disoproxil fumarate/emtricitabine 300/200 mg once daily from days 1-14; darunavir/ritonavir 800/100 mg once daily added on days 15-28
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily (post-hoc analysis)
Number of subjects: 23
Study: 20710088

Group type: EXPERIMENTAL
Intervention: Standardized treatment program including a 3-phase progressive strengthening program, manual stretching, thrust and nonthrust manipulation to the shoulder and spine, patient education, activity modification, and a daily home exercise program of stretching and strengthening.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standardized treatment program
Number of subjects: 10
Study: 20712386

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg/day, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day as needed
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40/25 mg/day
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ)
Number of subjects: 192
Study: 20713833

Group type: EXPERIMENTAL
Intervention: Liquor carbonis distillate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol cream
Number of subjects: 0
Study: 20713962

Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate 50 or 100 mg twice daily for 2 years
Number of subjects: 20
Study: 20714759

Group type: EXPERIMENTAL
Intervention: EVD drainage of CSF from ICP 20-25 to 10 mmHg
Number of subjects: 0
Study: 20716308

Group type: EXPERIMENTAL
Intervention: Alcohol craving assessed using the Penn Alcohol Craving Scale questionnaire
Number of subjects: 315
Study: 20716591

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg) plus Erlotinib (200 mg/day for non-EIAEDs; 500 mg/day for EIAEDs)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg) plus Erlotinib
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bevacizumab plus Erlotinib
Number of subjects: 57
Study: 20716769

Group type: EXPERIMENTAL
Intervention: Anti-cytokine autoantibodies
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 17
Study: 20718769

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25-hydroxy vitamin D levels)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) levels
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Vitamin D and PTH levels
Number of subjects: 783
Study: 20718983

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/TIVA group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Air/TIVA group
Number of subjects: 70
Study: 20719580

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20719837

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (nine sex- and age-matched children with idiopathic GH deficiency)
Number of subjects: 8
Study: 20719839

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment (hydrocortisone 26%, prednisolone 43%, dexamethasone 19%, combination 10%)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Anthropometric measurements
Number of subjects: 203

Group type: COMPARATOR
Intervention: Diastolic blood pressure measurements in women with classic CAH
Number of subjects: 203

Group type: COMPARATOR
Intervention: Metabolic health assessments
Number of subjects: 203

Group type: COMPARATOR
Intervention: Subjective health status evaluations
Number of subjects: 203
Study: 20720216

Group type: EXPERIMENTAL
Intervention: PHY906
Number of subjects: 0
Study: 20720224

Group type: EXPERIMENTAL
Intervention: Synchronous pulse trains across pairs of electrodes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Phase-shifted pulse trains (0.075, 0.375, 1.8, or 9 ms)
Number of subjects: 6
Study: 20721537

Group type: EXPERIMENTAL
Intervention: Memantine (10 to 30 mg/day)
Number of subjects: 29
Study: 20721933

Group type: EXPERIMENTAL
Intervention: Lower trabecular volumetric BMD at distal metaphyseal sites of the femur
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Lower trabecular volumetric BMD at distal metaphyseal sites of the tibia
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Prior fracture
Number of subjects: 465
Study: 20723856

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 51
Study: 20724537

Group type: EXPERIMENTAL
Intervention: M-dex + lenalidomide 15 mg/day
Number of subjects: 26
Study: 20724742

Group type: EXPERIMENTAL
Intervention: Inhalation of albuterol plus tiotropium
Number of subjects: 17
Study: 20725912

Group type: EXPERIMENTAL
Intervention: Colesevelam treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 20727190

Group type: EXPERIMENTAL
Intervention: Multipeptide vaccine in incomplete Freund's adjuvant (IFA)
Number of subjects: 36
Study: 20729251

Group type: EXPERIMENTAL
Intervention: Decision aid intervention to inform and support the choice between tube feeding and assisted oral feeding
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 256
Study: 20729729

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided algorithms
Number of subjects: 1131
Study: 20730365

Group type: EXPERIMENTAL
Intervention: Aquatic physical therapy for 10 minutes, involving movements to stimulate flexor posture and postural organization.
Number of subjects: 12